Atulya Deodhar, MD
Rheumatology · Portland, ORNPI 1558376053
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $503,285 of the $693,712 with a category attached, or 72.5%. It is spread thinly across 25 manufacturers, the largest accounting for just 16.3%. Reporting peaked in 2019 at $174,204 and has fallen 50.6% since, to $86,055 in 2025. Among rheumatology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 418 payments — averaging $1659.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$113K
- UCB, Inc.$98K
- Novartis$98K
- Novartis Pharma AG$97K
- Pfizer$73K
- Eli Lilly$69K
- plus $146K from 19 others
Across 253 payments — averaging $11,115 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.8M
- UCB SA$321K
- E.r. Squibb & Sons, L.L.C.$176K
- Eli Lilly$125K
- Pfizer$96K
- UCB, Inc.$86K
- plus $189K from 8 others
What the payments were for
- Consulting fees$503,28573%
- Speaking & faculty fees$122,54318%
- Travel & lodging$58,6578%
- Food & beverage$9,2011%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 38 | $112,792 |
| UCB, Inc. | 70 | $97,914 |
| Novartis | 64 | $97,649 |
| Novartis Pharma AG | 52 | $96,842 |
| Pfizer | 23 | $73,235 |
| Eli Lilly | 41 | $69,105 |
| GSK | 17 | $27,206 |
| Janssen Scientific Affairs, LLC | 21 | $25,013 |
| Johnson & Johnson | 25 | $24,452 |
| E.r. Squibb & Sons, L.L.C. | 20 | $19,075 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 2 | $14,275 |
| AbbVie | 3 | $8,300 |
| Amgen | 11 | $7,633 |
| Janssen Global Services, LLC | 3 | $5,463 |
| UCB Biosciences Inc. | 5 | $4,132 |
| Aurinia Pharma U.S., Inc. | 4 | $3,671 |
| Lilly USA, LLC | 3 | $3,164 |
| Cipla USA Inc. | 1 | $1,500 |
| Merck | 8 | $991 |
| Samsung Bioepis Co., Ltd. | 1 | $800 |
| AstraZeneca | 2 | $135 |
| Radius Health, Inc. | 1 | $125 |
| Sanofi | 1 | $121 |
| Genentech USA, Inc. | 1 | $108 |
| Sobi, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bimzelx$104,225
- COSENTYX$83,207
- AIN457F_COSENTYX_IMMUNOLOGY$71,357
- XELJANZ$58,504
- Tremfya$54,238
- Cimzia$30,367
- TALTZ$19,653
- Enbrel$8,675
- SECUKINUMAB_COSENTYX_DERMATOLOGY$8,670
- COSENTYX_COSENTYX_DERMATOLOGY$8,293
- ILARIS$6,815
- SIMPONI ARIA$6,181
- STELARA$6,181
- REMICADE$6,181
- LUPKYNIS$3,598
- Rinvoq$2,250
- DIOVAN$692
- CRH_COSENTYX_IMMUNOLOGY$640
- Tymlos$125
- KEVZARA$121
How this compares
$693,712 in reported general payments places this provider in the 95th percentile of 79 rheumatology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 84 | $633,591 |
| Taltz AutoinjectorIxekizumab | 46 | $430,668 |
| Humira(Cf) PenAdalimumab | 47 | $316,662 |
| XeljanzTofacitinib Citrate | 20 | $163,808 |
| Humira PenAdalimumab | 12 | $155,508 |
| Humira(Cf)Adalimumab | 21 | $147,736 |
| ActemraTocilizumab | 31 | $125,192 |
| OtezlaApremilast | 17 | $81,955 |
| Orencia ClickjectAbatacept | 12 | $79,551 |
| EnbrelEtanercept | 12 | $76,128 |
| BenlystaBelimumab | 20 | $28,166 |
| Hydroxychloroquine Sulfate | 50 | $2,533 |
| MethotrexateMethotrexate Sodium | 87 | $2,352 |
| Colchicine | 15 | $1,893 |
| Prednisone | 86 | $1,103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $8,300 | $781,327105 claims |
| PfizerXeljanz | $73,235 | $163,80820 claims |
| AmgenOtezla, Enbrel | $7,633 | $158,08329 claims |
| GSKBenlysta | $27,206 | $28,16620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 79 rheumatology providers in Oregon.
Other rheumatology in Portland
- Rosario BonafedePortland$148K
- James RosenbaumPortland$84K
- Kelly PortnoffPortland$13K
- Neha Rich-GargPortland$11K
- Cong Qiu ChuPortland$5K
- Rashmi ShahPortland$5K
- Caroline McCulleyPortland$4K
- John GriffinPortland$2K
- Whitney Elg-SalsmanPortland$981
- Anne VettoPortland$337
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.